☰

Matthew R. Janes, Ph.D. - Publications

Affiliations: 
2010 Biological Sciences - Ph.D. University of California, Irvine, Irvine, CA 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Gilardi M, Wang Z, Proietto M, Chillà A, Calleja-Valera JL, Goto Y, Vanoni M, Janes MR, Mikulski Z, Gualberto A, Molinolo AA, Ferrara N, Gutkind JS, Burrows F. Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas. Molecular Cancer Therapeutics. PMID 32727882 DOI: 10.1158/1535-7163.Mct-19-0958  0.478
2019 Molina-Arcas M, Moore C, Rana S, van Maldegem F, Mugarza E, Romero-Clavijo P, Herbert E, Horswell S, Li LS, Janes MR, Hancock DC, Downward J. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine. 11. PMID 31534020 DOI: 10.1126/Scitranslmed.Aaw7999  0.557
2019 Gualberto A, Scholz C, Mishra V, Janes MR, Kessler L, Cutsem EV, Ho AL, Witzig T. Abstract CT191: Mechanism of action of the farnesyltransferase inhibitor, tipifarnib, and its clinical applications Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct191  0.405
2019 Witzig T, Sokol L, Kim W, Foss F, Jacobsen E, de la Cruz Vincente F, Caballero D, Advani R, Roncero Vidal J, Marin-Niebla A, Rodriguez Izquierdo A, de Ona Navarrete R, Terol M, Domingo-Domenech E, Rodriguez M, ... ... Janes M, et al. TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY Hematological Oncology. 37: 64-65. DOI: 10.1002/Hon.32_2629  0.34
2018 Misale S, Fatherree JP, Cortez E, Li C, Bilton SJ, Timonina D, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan JD, Stein GT, Murchie E, ... ... Janes MR, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327306 DOI: 10.1158/1078-0432.Ccr-18-0368  0.554
2018 Hansen R, Firdaus SJ, Li S, Janes MR, Zhang J, Liu Y, Zarrinkar PP. An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors. Scientific Reports. 8: 14312. PMID 30254226 DOI: 10.1038/S41598-018-32683-W  0.476
2018 Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP. The reactivity-driven biochemical mechanism of covalent KRAS inhibitors. Nature Structural & Molecular Biology. PMID 29760531 DOI: 10.1038/S41594-018-0061-5  0.492
2018 Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 172: 578-589.e17. PMID 29373830 DOI: 10.1016/J.Cell.2018.01.006  0.495
2018 Gualberto A, Scholz C, Mishra V, Janes MR, Kessler L. Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients Blood. 132: 5349-5349. DOI: 10.1182/Blood-2018-99-116969  0.399
2018 Li L, Janes MR, Zhang J, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Feng J, Chen JH, Li S, Li S, Thach C, Liu Y, et al. Abstract 929: Discovery of novel covalent KRASG12C inhibitors that display high potency and selectivity in vitro and in vivo Cancer Research. 78: 929-929. DOI: 10.1158/1538-7445.Am2018-929  0.506
2018 Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li L, Ren P, Liu Y, Zarrinkar PP. Abstract 686: Drugging an undruggable pocket: The biochemical mechanism of covalent KRASG12C inhibitors Cancer Research. 78: 686-686. DOI: 10.1158/1538-7445.Am2018-686  0.488
2017 Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 127: 2438. PMID 28569734 DOI: 10.1172/JCI95182  0.764
2016 Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discovery. PMID 26739882 DOI: 10.1158/2159-8290.Cd-15-1105  0.438
2016 Kessler L, Chen J, Guo X, Hensen R, Patricelli M, Li S, Thach C, Darjania L, Li S, Wu T, Hu-Lowe D, Yao Y, Zarieh A, Janes M, Ely T, et al. KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics European Journal of Cancer. 69: S126. DOI: 10.1016/S0959-8049(16)32974-4  0.514
2015 Vo T, Lee JS, So L, Beagle B, Janes MR, Fruman DA. Abstract IA16: Mechanisms of resistance to mTOR inhibitors in leukemia and lymphoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Ia16  0.818
2014 Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. Plos One. 9: e88865. PMID 24586420 DOI: 10.1371/Journal.Pone.0088865  0.801
2013 Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CTH, Ong ST. Targeting of the MNK-eIF4E axis in blast crisis Chronic myeloid leukemia inhibits leukemia stem cell function Proceedings of the National Academy of Sciences of the United States of America. 110: E2298-E2307. PMID 23737503 DOI: 10.1073/Pnas.1301838110  0.667
2013 So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31. PMID 23275335 DOI: 10.1074/Jbc.M112.379446  0.755
2013 Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 27: 586-94. PMID 23090679 DOI: 10.1038/Leu.2012.276  0.748
2012 Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485: 55-61. PMID 22367541 DOI: 10.1038/Nature10912  0.434
2012 Janes MR, Fruman DA. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods in Molecular Biology (Clifton, N.J.). 821: 251-65. PMID 22125070 DOI: 10.1007/978-1-61779-430-8_15  0.674
2012 Janes MR, Guo X, Elia M, Staunton J, Jessen K, Rommel C, Liu Y. Abstract 2812: mTOR kinase mediates dissemination and colonization of breast cancer metastasis Cancer Research. 72: 2812-2812. DOI: 10.1158/1538-7445.Am2012-2812  0.447
2012 Kessler L, Jessen K, Janes M, Staunton J, Kucharski J, Guo X, Elia M, Banerjee U, Lan L, Wang S, Stewart J, Luzader A, Darjania L, Li L, Chan K, et al. Abstract 2745: INK128, a TORC1/2 kinase inhibitor, enhances the efficacy of cytotoxic therapies in endometrial tumor models Cancer Research. 72: 2745-2745. DOI: 10.1158/1538-7445.Am2012-2745  0.51
2011 Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. The Biochemical Journal. 439: 299-311. PMID 21767261 DOI: 10.1042/Bj20110853  0.64
2011 Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B. B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR. Molecular Endocrinology (Baltimore, Md.). 25: 933-43. PMID 21436254 DOI: 10.1210/Me.2010-0486  0.631
2011 Lim S, Saw TY, Chang S, Zhang M, Janes MR, Fruman DA, Rizzieri DA, Tan S, Chuah C, Ong ST. Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function Blood. 118: 963-963. DOI: 10.1182/Blood.V118.21.963.963  0.704
2011 Fruman DA, Janes MR, Mallya S, Vu CC, Shieh MP, Lilly MB, Sender LS, Martin MB, Ren P, Liu Y, Rommel C. The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models Blood. 118: 2585-2585. DOI: 10.1182/Blood.V118.21.2585.2585  0.73
2011 Jessen KA, Kessler L, Kucharski J, Guo X, Staunton J, Elia M, Janes M, Lan L, Wang S, Stewart J, Darjania L, Li L, Chan K, Martin M, Ren P, et al. Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer Cancer Research. 71: 4501-4501. DOI: 10.1158/1538-7445.Am2011-4501  0.748
2011 Kessler L, Jessen K, Janes M, Staunton J, Kucharski J, Guo X, Elia M, Banerjee U, Lan L, Wang S, Stewart J, Luzader A, Darjania L, Li L, Chan K, et al. Abstract A172: INK128, an orally active TORC1/2 kinase inhibitor, displays enhanced efficacy when combined with cytotoxic agents. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A172  0.555
2011 Jessen K, Kessler L, Kucharski J, Guo X, Staunton J, Janes M, Elia M, Banerjee U, Lan L, Wang S, Stewart J, Luzader A, Darjania L, Li L, Chan K, et al. Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A171  0.627
2010 Janes MR, Fruman DA. Targeting TOR dependence in cancer. Oncotarget. 1: 69-76. PMID 20657741 DOI: 10.18632/Oncotarget.110  0.695
2010 Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13. PMID 20072130 DOI: 10.1038/Nm.2091  0.809
2010 Fruman DA, Janes MR, Limon JJ, So L, Chen J, Martin MB, Ren P, Liu Y, Rommel C. Abstract 1798: TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than rapamycin Cancer Research. 70: 1798-1798. DOI: 10.1158/1538-7445.Am10-1798  0.818
2009 Janes MR, Fruman DA. Immune regulation by rapamycin: moving beyond T cells. Science Signaling. 2: pe25. PMID 19383976 DOI: 10.1126/Scisignal.267Pe25  0.625
2008 Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 118: 3038-50. PMID 18704194 DOI: 10.1172/Jci33337  0.802
Show low-probability matches.